

MMAI HEDIS 2020 Measures

	Measure/Data Element	2019 HEDIS Rate	2020 HEDIS Rate	Results Compared to	<u>Met</u> Goal	<u>Benchmark</u>	<u>Statisical</u> Significance
Brow	aution and Savanning			<u>Prev Yr</u>			
	<u>ention and Screening</u>	00.540/	l			05.1	
ABA	Adult BMI Assessment	80.54%	82.97%	↑	N	<25th	No Stat Change
BCS	Breast Cancer Screening	63.66%	65.64%	↑	N	<25th	No Stat Change
COL	Colorectal Cancer Screening	58.39%	51.82%	<u> </u>	N	<25th	No Stat Change
COA	Care for Older Adults (coa)						
	Advance Care Planning	17.76%	51.58%	^	Y	↑State Goal	Stat Significant↑
	Medication Review	47.45%	59.85%	1	N		Stat Significant↑
	Functional Status Assessment	37.71%	69.59%	↑	Y	↑State Goal	Stat Significant↑
	Pain Assessment	30.66%	66.18%	1	N		Stat Significant↑
Resp	piratory Conditions						
CWP	Appropriate Testing for Pharyngitis						
	Total		39.20%		N	<25th	
SPR	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	27.80%	21.05%	₩	N	<25th	No Stat Change
PCE	Pharmacotherapy Management of COPD Exacerbation						
	Systemic Corticosteroid	70.52%	66.24%	₩	N	<25th	No Stat Change
	Bronchodilator	85.55%	85.32%	↓	Y	>50th	No Stat Change
Caro	liovascular Conditions						
СВР	Controlling High Blood Pressure (cbp)	55.47%	45.99%	↓	N		Stat Significant↓
РВН	Persistence of Beta-Blocker Treatment After a Heart Attack	86.67%	97.37%	^	Y	>95th	No Stat Change
SPC	Statin Therapy for Patients With Cardiovascular Disease						
	Received Statin Therapy: Total	80.62%	87.30%	^	Y	>90th	Stat Significant↑
	Statin Adherence 80%: Total	71.22%	78.52%	<u>,</u>	N	>25th	Stat Significant↑
Diab	I .		10.02.1	·			
CDC	Comprehensive Diabetes Care						
020	Hemoglobin A1c (HbA1c) Testing	94.16%	93.67%	↓	N	>25th	No Stat Change
	(Inverted rate) HbA1c Poor Control (>9.0%)	40.63%	62.04%	↑	N	<25th	Stat Significant↑
ı	HbA1c Control (<8.0%)	51.58%	29.68%	→	N	<25th	Stat Significant √
	Medical Attention for Nephropathy	94.16%	95.13%	1	N	at 25th	No Stat Change
	BP Control (<140/90 mm Hg)	47.45%	55.47%	↑	N	>25th	Stat Significant↑
600	Eye Exam	67.88%	65.45%	<u> </u>	N	<25th	No Stat Change
SPD	Statin Therapy for Patients With Diabetes			•	••		
	Received Statin Therapy	77.97%	78.35%	↑	Y	>75th	No Stat Change
	Statin Adherence 80%	71.48%	72.31%	1	N	<25th	No Stat Change
	culoskeletal Conditions		1			1	
ART	Disease Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis	73.89%	76.50%	1	N	>25th	No Stat Change
OMW	Osteoporosis Management in Women Who Had a Fracture	13.21%	19.44%	1	N	<25th	No Stat Change
Med	ication Management and Care Coordination						
MRP	Medication Reconciliation Post-Discharge	16.30%	12.41%	. ↓	N	<25th	No Stat Change
TRC	Transition of Care						
	Notification of Inpatient Admission	2.43%	0.49%	. ↓	N	<25th	Stat Significant↓
	Receipt of Discharge Information	1.95%	0.49%	. ↓	N	<25th	No Stat Change
	Patient Engagement After Inpatient Discharge	48.18%	55.47%	↑	N	<25th	Stat Significant↑
	Medication Reconciliation Post-Discharge	12.90%	12.41%	↓	N	<25th	No Stat Change
FMC	Follow-Up After Emergency Department Visit for People With High-Risk Multiple						
	Chronic Conditions 7 day follow-after the ED visit: Total	53.93%	57.02%		Y	>50th	Stat Significant A
	/ day Jollow-after the ED VISIT: Total	33.93%	37.02%	<u> </u>	T	/50th	Stat Significant↑

Page 1 9/11/2020



MMAI HEDIS 2020 Measures

			4041.00				
	Measure/Data Element	2019 HEDIS Rate	2020 HEDIS Rate	Results Compared to Prev Yr	Met Goal	<u>Benchmark</u>	Statisical Significance
Beha	avioral Health						
AMM	Antidepressant Medication Management						
7	Antidepressant Medication Management - Effective Acute Phase Treatment	68.23%	67.15%	↓	N	>25th	No Stat Change
	Antidepressant Medication Management - Effective Continuation Phase Tx	53.02%	51.00%	↓	N N	>25th	No Stat Change
FUH	Follow-Up After Hospitalization for Mental Illness	33.0270	31.0070	<u> </u>	14	72501	140 Stat Change
гон	· · ·	44 200/	4E 200/	•	NI NI	↓ CMS Goal	No Stat Change
	30-Day Follow-Up	44.38%	45.28%	^	N N		No Stat Change
=110.0	7 days Follow Up	20.27%	23.99%	<u> </u>	N	>25th	No Stat Change
FUM	Follow-Up After Emergency Department Visits for Mental Illness	co/	== ==o/	•	.,	. ===	
	30-Day Follow-Up: Total	57.46%	57.55%	^	<u>Y</u>	>75th	No Stat Change
	7-Day Follow-Up: Total	44.78%	42.45%	<u> </u>	Y	>75th	No Stat Change
FUA	Follow-Up After Emergency Department Visits for Alcohol & Other Drug Dependence						
	30-Day Follow-Up	16.480%	15.92%	↓	Y	>50th	No Stat Change
	7 days Follow Up	10.44%	12.74%	^	Y	>75th	No Stat Change
FUI	Follow-Up After High-Intensity Care for Substance Use Disorder						
	30-Day Follow-Up		39.76%			New	
	7 days Follow Up		24.10%			New	
POD	Pharmacotherapy for Opioid Use Disorder		35.29%			New	
SAA	Adherence to Antipsychotic Medications for Individuals with Schizophrenia		78.06%			New	
	ruse/ Appropriateness		78.00%			INEW	
		24.740/	20.070/			42E4F	Charles and A
PSA	Non-Recommended PSA-Based Screening in Older Men (Inverted rates)	24.74%	28.97%	^	N	<25th	Stat Significant↑
URI	Appropriate Treatment for Upper Respiratory Infection						
	Total		66.03%			New	
AAB	Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis						
	Total		29.60%			New	
DDE	Potentially Harmful Drug-Disease Interactions in the Elderly (Inverted rates)						
	Total	38.16%	34.13%	. ↓	Y	>75th	Stat Significant↓
DAE	Use of High Risk Medications in Older Adults (Inverted rates)	9.26%	11.76%	Ψ	N	>25th	Stat Significant↑
HDO	Use of Opioids at High Dosage (Inverted rates)		4.26%		N	>50th	
UOP	Use of Opioids From Multiple Providers (Inverted rates)						
	(Inverted rates) Multiple Prescribers	16.47%	18.37%	1	N	<25th	No Stat Change
	(Inverted rates) Multiple Pharmacies	5.85%	3.62%	Ψ	N	>25th	Stat Significant↓
	(Inverted rates) Multiple Prescribers and Multiple Pharmacies	3.01%	1.77%	Ψ	N	>25th	Stat Significant↓
сои	Risk of Continued Opioid Use						
	>=15 Days covered		14.76%			New	
	>=31 Days covered		6.81%			New	
Acce	ess/Availability of Care					2	
AAP	Adults' Access to Preventive/Ambulatory Health Services						
AAF	Adults' Access to Preventive/Ambulatory Health Services (Total)	94.55%	95.17%	1	N	>25th	
IET		34.33%	33.1770	T	IN	/2JUI	
IET	Initiation and Engagement of AOD Dependence Treatment	44.040/	42.000/	↓	N1	J.Cr. C.	No Stat Share
	Initiation of AOD Treatment: Total	44.94%	43.89%		N		No Stat Change
B' '	Engagement of AOD Treatment: Total	10.12%	8.83%	↓	N		No Stat Change
	Adjusted Utilization						
PCR	All Plan Cause Readmissions						
	O/E Ratio: 18-64 Total		3.03571			Revised	
	O/E Ratio: 65+ Total		2.68228			Revised	

Page 2 9/11/2020